Terns Pharmaceuticals, Inc. (TERN)
| Market Cap | 235.22M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 25.11M |
| EPS (ttm) | -3.39 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 39,627 |
| Open | 9.63 |
| Previous Close | 9.62 |
| Day's Range | 9.13 - 9.57 |
| 52-Week Range | 6.92 - 28.36 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 20.00 (+113.7%) |
| Est. Earnings Date | Nov 11, 2021 |
About TERN
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. It develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase I clinical trial for the treatment of NASH. The company also develops TERN-501, a thyroi...
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for TERN stock is "Buy." The 12-month stock price forecast is 20.00, which is an increase of 113.68% from the latest price.
News
Terns Pharmaceuticals to Present Positive Clinical Data on NASH Programs at AASLD The Liver Meeting® Digital Experien...
FOSTER CITY, Calif., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-m...
Terns Pharmaceuticals to Present at H.C. Wainwright 5th Annual NASH Investor Conference
FOSTER CITY, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-m...
Terns Appoints Veteran Biopharmaceutical Executive Ann E. Taylor, M.D.
FOSTER CITY, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-...
Terns Completes Part 1 Enrollment of AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201
- TERN-201 is a highly selective VAP-1 inhibitor intended to address chronic liver inflammation and fibrosis in NASH
Terns Pharmaceuticals to Present at Upcoming Investor Conferences
FOSTER CITY, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-...
Terns Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights
FOSTER CITY, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-m...
Terns Announces Initiation of Patient Dosing in AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201
FOSTER CITY, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-m...
Terns Shares Drop After Mixed Results From Mid-Stage NASH Trial With FXR Agonist
Terns Pharmaceuticals Inc (NASDAQ: TERN) reported top-line results from the Phase 2a LIFT trial of TERN-101, a liver-distributed farnesoid X receptor (FXR) agonist for the treatment of patients with non...
Terns Reports Positive Top-line Results from Phase 2a LIFT Study of FXR Agonist TERN-101 in Patients with NASH
First FXR agonist trial to demonstrate no discontinuations due to AEs, including pruritus, and both a differentiated pruritus and lipid profile in patients with NASH
Terns Pharmaceuticals to Host Conference Call to Discuss Top-line Results from Phase 2a LIFT Study of TERN-101 for Tr...
FOSTER CITY, Calif., June 13, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-m...
Terns to Present at the UBS Global Healthcare Virtual Conference & Participate in the J.P. Morgan Biotech 2021 CEO Co...
FOSTER CITY, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-mo...
Terns to Present at the 19th Annual Virtual Needham HealthCare Conference
FOSTER CITY, Calif., April 07, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-...
Terns Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
-Terns ended 4Q 2020 with $75 million in cash and cash equivalents and completed an upsized initial public offering in February 2021, raising approximately $147 million in gross proceeds to support oper...
Terns Announces Initiation of Dosing in Phase 1 Clinical Trial of TERN-501, its THR-Beta Agonist in Development for t...
-TERN-501 is designed to have high metabolic stability, enhanced liver distribution and high selectivity for THR- β-
Terns to Present at the Cowen 41st Annual Health Care Conference
FOSTER CITY, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-m...
Terns Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Exercise in Full of Underwriters' Option...
FOSTER CITY, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-m...
Terns Pharmaceuticals, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock Nasdaq:TERN
FOSTER CITY, Calif. -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage...
Terns Pharmaceuticals, Inc. Announces Proposed Initial Public Offering of Common Stock
FOSTER CITY, Calif.--Terns Pharmaceuticals, Inc. (“Terns” or the “Company”), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy cand...
Terns Pharmaceuticals IPO Registration Document (S-1)
Terns Pharmaceuticals, Inc. has filed to go public with an IPO on the NASDAQ.
NASH biotech Terns Pharmaceuticals files for a $100 million IPO
Terns Pharmaceuticals, a Phase 2 biotech developing small molecule therapies for NASH, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Terns Completes Enrollment in Phase 2a Clinical Trial of TERN-101 in NASH Patients
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy...